SV

Street Verdict

Analyst Scorecard

ALKEM · NSE

Alkem Laboratories Limited

₹5,185

+0.78% (+₹40)

Prev. close

₹5,145

Volume

69,594

Delivery %

41.5%

As of

20 Nov 2026

Price history

₹5,185-₹290 (-5.30%) · 3M
18 Aug 2026 → 20 Nov 2026
5,0005,1005,2005,3005,40018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Alkem Laboratories Limited

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Basudeo Narian Singh

Headquarters

Mumbai

Employees

19,346

Key stats

Market cap

₹61,791.19 Cr

P/E ratio (TTM)

29.1

Dividend yield

0.38%

EPS (TTM)

₹177.65

Beta (1Y · daily vs NIFTY 50)

0.68

Beta (5Y · monthly vs NIFTY 50)

0.76

Shares float

4.61 Cr

EPS · quarter ended Jun 2026

₹43.49

Financial Performance

01 · Financials

0 Cr5000 Cr10000 Cr15000 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

050100150200₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0204060₹-50%0%50%100%13 Feb 2010 Aug 2011 Feb 2109 Aug 2110 Feb 2208 Aug 2217 Feb 2310 Aug 2316 Feb 2409 Aug 2414 Feb 2508 Aug 2520 Feb 2607 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-25%0%25%50%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr10000 Cr20000 Cr30000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr10000 Cr20000 Cr30000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr1000 Cr2000 Cr3000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹10,796.84 Cr₹11,815.34 Cr₹12,978.42 Cr₹13,458.26 Cr₹15,295.62 Cr
₹8,937.60 Cr₹10,407.59 Cr₹10,833.80 Cr₹10,931.23 Cr₹12,249.90 Cr
₹1,844.28 Cr₹1,304.77 Cr₹2,023.13 Cr₹2,527.03 Cr₹2,870.89 Cr
3 Profit before exceptional items and tax (1) - (2)
₹1,859.24 Cr₹1,407.75 Cr₹2,144.62 Cr₹2,527.03 Cr₹3,045.72 Cr
4 Exceptional items
₹-14.96 Cr₹-102.98 Cr₹-121.49 Cr—₹-174.83 Cr
₹163.96 Cr₹297.96 Cr₹211.67 Cr₹311.03 Cr₹517.76 Cr
8 Profit attributable to Non-Controlling Interest
₹34.70 Cr₹22.64 Cr———
9 Profit attributable to Owners of the Company (7) - (8)
₹1,645.62 Cr₹984.17 Cr———
7 Share in loss after tax of associate
———₹-62.00 L₹-1.97 Cr
8 Profit for the year (5) - (6) + (7)
₹1,680.32 Cr₹1,006.81 Cr₹1,811.46 Cr₹2,215.38 Cr₹2,351.16 Cr
(a) (i) Items that will not be reclassified subsequently to profit or loss
₹-9.09 Cr₹-4.87 Cr₹-9.34 Cr₹-21.81 Cr₹12.09 Cr
(ii) Income tax relating to items that will not be reclassified to profit or loss
₹3.32 Cr₹1.61 Cr₹2.98 Cr₹7.21 Cr₹-3.81 Cr
(b) (i) Items that will be reclassified to profit or loss
₹39.91 Cr₹118.16 Cr₹26.40 Cr₹34.32 Cr₹175.51 Cr
11 Other Comprehensive Income/(Loss) attributable to Non-Controlling Interest
₹-41.00 L₹-41.00 L———
12 Other Comprehensive Income/(Loss) attributable to Owners of the Company (10) - (11)
₹34.55 Cr₹115.31 Cr———
14 Total Comprehensive Income/(Loss) attributable to Non-Controlling Interest (8) + (11)
₹34.29 Cr₹22.23 Cr———
15 Total Comprehensive Income/(Loss) attributable to Owners of the Company (13) - (14)
₹1,680.17 Cr₹1,099.48 Cr———
Total other comprehensive income for the year (net of tax)
₹34.14 Cr₹114.90 Cr₹20.04 Cr₹19.72 Cr₹183.79 Cr
10 Total comprehensive income for the year (8) + (9)
₹1,714.46 Cr₹1,121.71 Cr₹1,831.50 Cr₹2,235.10 Cr₹2,534.95 Cr
Owners of the Company
——₹1,795.77 Cr₹2,165.48 Cr₹2,301.80 Cr
Non-controlling interests
——₹15.69 Cr₹49.90 Cr₹49.36 Cr
Owners of the Company
——₹20.65 Cr₹20.75 Cr₹182.38 Cr
Non-controlling interests
——₹-61.00 L₹-1.03 Cr₹1.41 Cr
Owners of the Company
——₹1,816.42 Cr₹2,186.23 Cr₹2,484.18 Cr
Non-controlling interests
——₹15.08 Cr₹48.87 Cr₹50.77 Cr
14 Basic and diluted earnings per share
137.6382.31150.19181.11192.51

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹11,519.26 Cr₹14,069.19 Cr₹13,756.65 Cr₹15,574.90 Cr₹17,691.10 Cr₹20,872.97 Cr
₹11,519.26 Cr₹14,069.19 Cr₹13,756.65 Cr₹15,574.90 Cr₹17,691.10 Cr₹20,872.97 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY22FY23FY24FY25FY26
₹1,111.02 Cr₹1,682.50 Cr₹1,948.07 Cr₹1,912.84 Cr₹1,963.03 Cr
₹-1,435.13 Cr₹112.84 Cr₹-1,008.50 Cr₹-1,298.76 Cr₹-1,667.21 Cr
₹55.46 Cr₹34.52 Cr₹-205.44 Cr₹-196.91 Cr₹-207.58 Cr
E Cash Cash Equivalents as at the beginning of the year (net of loans repayable on demand from banks)
₹174.22 Cr₹232.18 Cr₹273.80 Cr₹66.31 Cr₹-120.09 Cr
Add/Less: Effect of exchange difference on foreign currency cash and cash equivalents
₹2.50 Cr₹7.10 Cr₹-2.05 Cr₹10.51 Cr₹-14.46 Cr
Cash and cash equivalents as at end of the year (D+E) (Refer Note 3.9)
₹232.18 Cr₹273.80 Cr———
F Cash Cash Equivalents as at the end of the year (net of loans repayable on demand from banks) (D+E) (Refer Note 3 below)
——₹66.31 Cr₹-120.09 Cr₹-342.13 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21–Mar 22(2Q)Jun 22Sep 22–Jun 23(4Q)Sep 23–Mar 24(3Q)Jun 24Sep 24–Dec 24(2Q)Mar 25Jun 25Sep 25–Mar 26(3Q)Jun 26
Promoter58.84%57.13%57.14%57.16%56.74%56.38%55.66%55.13%53.04%51.20%49.70%
Public41.16%42.87%42.86%42.84%43.26%43.62%44.34%44.87%46.96%48.80%50.30%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Alkem Laboratories Limited₹61,791.19 Cr₹5,216.529.14.4716.7%0.15+13.5%-7.9%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

ALKEM

Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility

Upstox · 3 days ago

ALKEM

Alkem Laboratories Q2 FY27 Earnings Call Key Highlights

Kalkine India · 5 days ago